Clinical Trial Update: Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of bevacizumab for recurrent respiratory papillomatosis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Papillomatosis

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Recurrent Respiratory Papillomatosis | Phase 1 | Status: COMPLETED | Results posted: 2012-12-04